327 related articles for article (PubMed ID: 19020921)
1. Differences in persistence among different weekly oral bisphosphonate medications.
Sheehy O; Kindundu CM; Barbeau M; LeLorier J
Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
[TBL] [Abstract][Full Text] [Related]
2. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Ringe JD; Möller G
Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
[TBL] [Abstract][Full Text] [Related]
3. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
4. The association between automatic generic substitution and treatment persistence with oral bisphosphonates.
Ström O; Landfeldt E
Osteoporos Int; 2012 Aug; 23(8):2201-9. PubMed ID: 22120909
[TBL] [Abstract][Full Text] [Related]
5. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
8. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
9. Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
Ström O; Landfeldt E; Garellick G
Osteoporos Int; 2015 Jan; 26(1):315-25. PubMed ID: 25297890
[TBL] [Abstract][Full Text] [Related]
10. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Pazianas M; Abrahamsen B; Wang Y; Russell RG
Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
[TBL] [Abstract][Full Text] [Related]
11. Persistence with osteoporosis medication among newly-treated osteoporotic patients.
van Boven JF; de Boer PT; Postma MJ; Vegter S
J Bone Miner Metab; 2013 Sep; 31(5):562-70. PubMed ID: 23575910
[TBL] [Abstract][Full Text] [Related]
12. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
[No Abstract] [Full Text] [Related]
13. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
14. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
Emkey R
MedGenMed; 2004 Jul; 6(3):6. PubMed ID: 15520628
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann M; Reginster JY
Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
[TBL] [Abstract][Full Text] [Related]
16. Medication persistence with weekly versus daily doses of orally administered bisphosphonates.
Ettinger MP; Gallagher R; MacCosbe PE
Endocr Pract; 2006; 12(5):522-8. PubMed ID: 17002926
[TBL] [Abstract][Full Text] [Related]
17. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
[TBL] [Abstract][Full Text] [Related]
18. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
20. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
